⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BYSI News
BeyondSpring Inc. Ordinary Shares
Form 8-K
sec.gov
BYSI
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
BYSI
Form 8-K/A
sec.gov
BYSI
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
globenewswire.com
BYSI
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
globenewswire.com
BYSI
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
globenewswire.com
BYSI
Form 8-K
sec.gov
BYSI
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
BYSI
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
globenewswire.com
BYSI
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
globenewswire.com
BYSI